25I-NBOH (2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-hydroxyphenyl)methyl]ethanamine) is a synthetic psychedelic phenethylamine belonging to the NBOH series and representing the direct NBOH analog of 25I-NBOMe — the most potent and most dangerous of the major NBOMe compounds. It is active at microgram doses through potent 5-HT2A agonism and is only active via sublingual or buccal administration.
25I-NBOH represents the iodinated member of the NBOH series, and within the NBOH family it is expected to be among the most potent based on the consistent structure-activity relationship seen across the 2C and NBOMe series: 4-iodo substitution generally confers the highest 5-HT2A binding affinity among the common 4-halo variants. The compound's pharmacology is broadly described as very similar to 25I-NBOMe but with lower physical toxicity — the 2-hydroxybenzyl group appears to reduce the severe vasoconstriction associated with the 2-methoxybenzyl group of NBOMe compounds.
No confirmed fatalities specifically from 25I-NBOH have been documented, representing a meaningful contrast to 25I-NBOMe which has one of the highest confirmed death tolls among novel psychoactive substances. However, this relative safety advantage does not eliminate risk: 25I-NBOH is extremely potent, carries all the characteristic hazards of microgram-dosed psychedelics with steep dose-response curves, and is physically indistinguishable from NBOMe blotters without testing. Any blotter that tests negative for indoles should not be assumed to be the "safer" NBOH variant.
Safety at a Glance
High Risk- Do Not Assume NBOH is Safe
- Test Your Substance
- Toxicity: Acute Toxicity Profile No confirmed fatalities specifically attributed to 25I-NBOH alone have been documented in the ...
- Overdose risk: LD50potentially fatal at heavy dosages. 25I-NBOH's extreme potency means it should not be insuffl...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
sublingual
Duration
sublingual
Total: 5 hrs – 8 hrsHow It Feels
Within twenty minutes, a sharpening of the visual field announces the arrival of the experience. Colors begin to pop with increasing intensity -- reds deepen, greens fluoresce, and blues acquire an electric depth. A mild stimulant energy builds in the chest and limbs, but it carries none of the vasoconstriction-heavy body load that makes its NBOMe counterpart so physically demanding. The body feels energized but not wired, alert but not tense. There is an anticipatory excitement as the visual effects begin to accelerate.
By the one-hour mark, the visual component has blossomed into something spectacular. 25I-NBOH is among the most visually potent compounds in the NBOx series, and at the peak it delivers a torrent of geometric complexity that rivals 25I-NBOMe without the punishing physical cost. Intricate, symmetrical patterns tile across every surface -- elaborate mandalas, crystalline lattices, and spiraling fractals that pulse and shift with mechanical precision. Colors are vivid beyond natural possibility, glowing with an internal luminance that makes the world appear rendered in stained glass. Afterimages trail behind moving objects in prismatic ribbons. The visual field seems to contain more information than the eyes normally process, as though the brain's pattern-recognition systems have been pushed into overdrive.
The headspace is remarkably clear for the level of visual intensity. Thoughts are lucid, organized, and gently accelerated. There is a euphoric brightness to the mood -- a sense of wonder and engagement with the visual spectacle that maintains its novelty throughout the peak. Music is dramatically enhanced, with sounds seeming to generate visual counterparts in real time. Socially, the experience lends itself to animated conversation and shared exploration of the altered perceptual landscape. The body load, while not absent, is manageable: mild jaw tension, a slight elevation in heart rate, and occasional waves of warmth. Compared to 25I-NBOMe, the physical experience is noticeably more comfortable, allowing greater attention to be directed toward the extraordinary visual content.
The peak sustains for two to three hours before gradually subsiding. The geometric overlays thin and eventually fade, leaving behind hours of enhanced color perception and gentle visual shimmer. The stimulant component eases into a calm alertness. Total duration spans six to eight hours. The comedown is smooth and the aftermath is surprisingly clean -- mild fatigue, perhaps, but little of the physical wreckage that the NBOMe compounds can leave in their wake.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(27)
- Abnormal heartbeat— Abnormal heartbeat (arrhythmia) is any deviation from the heart's normal rhythm — including beats th...
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
- Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased bodily temperature— Increased bodily temperature (hyperthermia) is an elevation of core body temperature above the norma...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
- Mouth numbing— Mouth numbing is a localized loss of sensation in the tongue, gums, cheeks, and surrounding oral tis...
- Muscle cramp— Muscle cramps are sudden, involuntary, and often painful contractions of muscles that occur as a sid...
- Muscle tension— Persistent partial contractions or tightening of muscles that produces uncomfortable stiffness, cram...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Restless legs— Restless legs is an uncomfortable neurological effect characterized by an irresistible compulsion to...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Stomach cramp— Stomach cramps are sharp, intermittent pains in the abdominal region that can occur when psychoactiv...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Cognitive & Perceptual Effects
Visual(22)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Brightness alteration— Perceived increase or decrease in environmental brightness beyond actual illumination levels, common...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour replacement— A visual phenomenon in which the colors of objects or the entire visual field are statically replace...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Frame rate suppression— Perception of visual motion as choppy discrete frames rather than smooth continuous flow, resembling...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Magnification— A visual distortion in which objects appear larger or closer than they actually are, as though one's...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Recursion— The visual field begins to repeat and nest within itself in a self-similar, fractal-like manner, as ...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(16)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Feelings of impending doom— Feelings of impending doom is the sudden onset of an overwhelming, visceral certainty that something...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Increased sense of humor— A general amplification of one's sensitivity to finding things humorous and amusing, often causing p...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Auditory(4)
- Auditory distortion— Auditory distortion is the experience of sounds becoming warped, pitch-shifted, flanged, or otherwis...
- Auditory enhancement— Auditory enhancement is a heightened sensitivity and appreciation of sound in which music, voices, a...
- Auditory hallucination— Auditory hallucination is the perception of sounds that have no external source — hearing music, voi...
- Auditory misinterpretation— Auditory misinterpretation is the brief, spontaneous misidentification of real sounds as entirely di...
Multi-sensory(6)
- Dosage independent intensity— Dosage independent intensity is the uncommon and poorly understood phenomenon in which a person expe...
- Gustatory hallucination— Gustatory hallucinations are phantom taste experiences in which distinct flavors manifest in the mou...
- Machinescapes— Machinescapes are complex multisensory hallucinations involving the perception of enormous mechanica...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Sensory overload— An overwhelming flood of sensory information that exceeds the brain's ability to process, creating a...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(3)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
25I-NBOH acts as a potent full agonist at serotonin 5-HT2A receptors, with particularly high selectivity for serotonin receptors over other receptor systems. Among NBOH analogs, 25I-NBOH is expected to have the highest 5-HT2A binding affinity based on the iodo-4 substitution, consistent with the known structure-activity relationship across the halogenated phenethylamine family.
NBOH vs NBOMe Pharmacology
The key pharmacological distinction between NBOH and NBOMe compounds is in the N-substituent: NBOH uses a 2-hydroxybenzyl group while NBOMe uses a 2-methoxybenzyl group. Both dramatically increase 5-HT2A binding affinity over the parent phenethylamine, but they differ in their interaction with adrenergic receptors. NBOMe compounds have stronger alpha-adrenergic effects, which is believed to account for their greater vasoconstriction toxicity. NBOH compounds retain potent 5-HT2A agonism with comparatively reduced vasoconstriction — this is the pharmacological basis for the comparatively lower acute toxicity risk of NBOH vs NBOMe.
Route of Administration
Active only sublingually or buccally. Blotter must be held under the tongue for 15–20 minutes.
Pharmacokinetics
No formal human pharmacokinetic data are available. By analogy with 25I-NBOMe and other NBOH compounds, onset is expected within 20–45 minutes, peak effects at 2–3 hours, and total duration of 5–8 hours. Hepatic CYP450 metabolism is presumed.
Tolerance
Cross-tolerance with LSD, psilocybin, mescaline, and other serotonergic psychedelics is expected. A gap of at least 5–7 days between uses is recommended.
Detection Methods
Urine Detection
25I-NBOH is not targeted by standard immunoassay-based urine drug screens. However, due to its phenethylamine backbone, there is a theoretical possibility of cross-reactivity with amphetamine immunoassays, though this has not been consistently reported in clinical literature. Specialized LC-MS/MS methods developed for novel psychoactive substances can detect NBOH compounds and their metabolites in urine for approximately 24 to 48 hours after ingestion, depending on dose and individual metabolism.
Blood and Serum Detection
Blood detection windows for 25I-NBOH are relatively short. Peak plasma concentrations occur within 30 minutes to 2 hours depending on the route of administration (sublingual absorption is typical for NBOH compounds). Blood concentrations fall below detectable thresholds within 6 to 16 hours for most methods. LC-MS/MS remains the only reliable analytical approach for serum detection, as the doses involved (typically hundreds of micrograms to low milligrams) produce low absolute concentrations.
Standard Drug Panel Inclusion
25I-NBOH is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. It is not specifically targeted by any routine workplace or clinical immunoassay. While some structural similarity to amphetamines exists, cross-reactivity on amphetamine panels is inconsistent and cannot be relied upon for either detection or exclusion. Identification requires specific testing at a reference laboratory equipped for novel psychoactive substance analysis.
Confirmatory Methods
Definitive identification of 25I-NBOH requires LC-MS/MS or high-resolution mass spectrometry (HRMS). GC-MS can also be employed but may require derivatization due to the thermal lability of NBOH compounds. Reference standards are necessary for quantitative confirmation. Forensic and clinical toxicology laboratories that maintain novel psychoactive substance panels are the only facilities reliably capable of this analysis.
Reagent Testing (Harm Reduction)
Reagent testing is critically important for NBOH compounds due to their significantly higher toxicity profile compared to classical psychedelics. The Ehrlich reagent shows NO reaction with 25I-NBOH, which is the single most important distinguishing test: any substance sold as a psychedelic that fails to turn purple with Ehrlich may be an NBOH compound rather than LSD or a tryptamine. The Marquis reagent produces variable results depending on the specific NBOH compound, ranging from no reaction to green or brown color changes. The Mecke reagent may produce a brown or dark green reaction. For harm reduction purposes, always testing with Ehrlich first is essential. The absence of a purple Ehrlich reaction is a strong warning sign that the substance is not a lysergamide or tryptamine and may be a potentially dangerous NBOH compound.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Development
25I-NBOH was developed as part of the systematic NBOH series research following Ralf Heim's original NBOMe work. The NBOH variant of the iodinated compound (25I) was characterized in radioligand binding studies and compared to its NBOMe counterpart. The higher potency of the iodo-4 variant was confirmed by binding data.
Research Context
25I-NBOH was used in pharmacological research as a reference compound for 5-HT2A receptor studies, alongside 25I-NBOMe. Its comparative study helped illuminate the pharmacological differences between the hydroxybenzyl and methoxybenzyl N-substituents.
Prevalence
25I-NBOH appears in drug checking databases significantly less frequently than 25I-NBOMe. Community reports describe it as rare but present in certain blotter markets.
Legal Status
Controlled under analog legislation in most jurisdictions. Specific scheduling status varies internationally.
Harm Reduction
Do Not Assume NBOH is Safe
The absence of documented NBOH fatalities does not mean NBOH compounds are safe. It reflects that NBOH compounds are significantly less prevalent in drug markets than NBOMe compounds, and that the available safety margin, while somewhat wider, is not wide. All harm reduction principles applicable to NBOMe compounds apply to NBOH.
Test Your Substance
Ehrlich reagent: absence of purple-violet color indicates no indole compound. A negative Ehrlich test does NOT confirm NBOH identity — it only excludes LSD and psilocybin. Use mass spectrometry for definitive identification. Critically, a negative Ehrlich test cannot distinguish between NBOMe and NBOH compounds, meaning you cannot use reagent testing alone to verify the "safer" NBOH variant.
Sublingual Administration Only
Hold blotter under the tongue for 15–20 minutes. The compound is inactive when swallowed.
Conservative Dosing
- Threshold: ~150–300 μg
- Common: 300–600 μg
- 25I-NBOH is expected to be among the more potent NBOH analogs; start with the minimum possible fraction of a blotter on first exposure
- Do not redose within 90 minutes
Monitor for Vasoconstriction
Check extremity warmth and color. Cold or blue digits are a warning sign warranting warming environment and cessation of physical activity.
Dangerous Combinations to Avoid
- Stimulants: compound vasoconstriction
- Lithium: seizure risk
- MAOIs: serotonin syndrome
- Cannabis: extreme intensity amplification
Toxicity & Safety
Acute Toxicity Profile
No confirmed fatalities specifically attributed to 25I-NBOH alone have been documented in the scientific literature. This contrasts with 25I-NBOMe, which has one of the highest confirmed death tolls among novel psychoactive substances. The NBOH modification is believed to reduce severe vasoconstriction risk relative to NBOMe, which is the primary mechanism of acute fatality.
Vasoconstriction
While less severe than NBOMe compounds, vasoconstriction remains a documented and clinically significant effect of NBOH compounds, including 25I-NBOH. It manifests as cold, pale, or blue extremities and is exacerbated by stimulant co-use.
Cardiovascular Effects
Tachycardia and elevated blood pressure are expected effects. Those with cardiovascular conditions are at elevated risk.
Psychological Risks
25I-NBOH can produce very intense psychedelic experiences at modest doses due to its high potency. Acute panic, paranoia, and psychological crisis are documented adverse events.
Drug Interactions
- Stimulants — Strongly contraindicated; compound vasoconstriction
- Lithium — Absolutely contraindicated
- MAOIs — Avoid; serotonin syndrome risk
- Cannabis — Dramatically amplifies intensity; significant crisis risk
Contraindications
- Cardiovascular disease or vascular disorders
- Personal or family history of psychotic disorders
- Current use of stimulants, lithium, or MAOIs
Addiction Potential
not habit-forming
Overdose Information
LD50potentially fatal at heavy dosages.
25I-NBOH's extreme potency means it should not be insufflated (snorted) as this method of administration has been associated with many deaths and hospitalizations with the closely related 25I-NBOMe.
25I-not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of 25I-almost immediately after ingestion. After that,12 weeks to be back at baseline (in the absence of further consumption). 25I-NBOH presents cross-tolerance with Cross-all psychedelics, meaning that after the consumption of 25I-NBOH all psychedelics will have a reduced effect.
Germany: 25I-NBOH is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Sweden: The Riksdag added 25I-NBOH to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of August 18, 2015, published by Medical Products Agency (MPA) in regulation HSLF-FS 2015:12
Switzerland: 25I-NBOH is a controlled substance specifically named under Verzeichnis E.
United Kingdom: 25I-NBOH is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.
Responsible use
Research chemical
Psychedelics
Phenethylamines
25I-NBOMe
25I-NBOH (Wikipedia)
25I-NBOH (Isomer Design)
The Big & Dandy 25I-NBOH Thread (Bluelight)
==Refe
Tolerance
| Full | almost immediately after ingestion |
| Half | 1 week |
| Zero | 2 weeks |
Cross-tolerances
Legal Status
Germany: 25I-NBOH is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Sweden: The Riksdag added 25I-NBOH to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of August 18, 2015, published by Medical Products Agency (MPA) in regulation HSLF-FS 2015:12
Switzerland: 25I-NBOH is a controlled substance specifically named under Verzeichnis E.
United Kingdom: 25I-NBOH is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.
Responsible use
Research chemical
Psychedelics
Phenethylamines
25I-NBOH (Wikipedia)
25I-NBOH (Isomer Design)
The Big & Dandy 25I-NBOH Thread (Bluelight)
Experience Reports (1)
Tips (3)
Keep a benzodiazepine like alprazolam on hand as an emergency trip abort tool when using 25I-NBOH. Even just knowing you have one available provides psychological reassurance. It will not fully end the trip but significantly reduces intensity.
People with a personal or family history of psychotic disorders (schizophrenia, bipolar type I) should avoid 25I-NBOH and other psychedelics. These substances can trigger or exacerbate psychotic episodes in predisposed individuals.
Set and setting are paramount with 25I-NBOH. Choose a familiar, comfortable environment where you feel safe. Have trusted company or a trip sitter, especially for your first experience. Avoid stressful locations or social obligations.
See Also
Same Class
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 25I-NBOH - TripSit Factsheet
TripSit factsheet for 25I-NBOH
tripsit - 25I-NBOH - Wikipedia
Wikipedia article on 25I-NBOH
wikipedia